Milestone Pharmaceuticals Inc
NASDAQ:MIST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Milestone Pharmaceuticals Inc
Operating Income
Milestone Pharmaceuticals Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Milestone Pharmaceuticals Inc
NASDAQ:MIST
|
Operating Income
-$62.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Operating Income
$2.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
0%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Operating Income
-CA$52.8m
|
CAGR 3-Years
57%
|
CAGR 5-Years
42%
|
CAGR 10-Years
-9%
|
|
|
Cronos Group Inc
TSX:CRON
|
Operating Income
-$14.6m
|
CAGR 3-Years
48%
|
CAGR 5-Years
39%
|
CAGR 10-Years
-23%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Operating Income
-$151.2m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-123%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Operating Income
CA$5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Milestone Pharmaceuticals Inc
Glance View
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 29 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate is etripamil. The etripamil is a novel, potent and short-acting calcium channel blocker that has been designed rapid-onset nasal spray, which is self-administered by patients. The firm is developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF) and rapid ventricular rate, and other cardiovascular indications.
See Also
What is Milestone Pharmaceuticals Inc's Operating Income?
Operating Income
-62.1m
USD
Based on the financial report for Dec 31, 2025, Milestone Pharmaceuticals Inc's Operating Income amounts to -62.1m USD.
What is Milestone Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-4%
Over the last year, the Operating Income growth was -48%. The average annual Operating Income growth rates for Milestone Pharmaceuticals Inc have been -1% over the past three years , -4% over the past five years .
